Objective: To explore the clinical efficacy and safety of targeted drugs sorafenib combined with stereotactic radiotherapy for lung metastasis of liver cancer. Methods: January 2013 ~2015 year in January in our hospital of liver cancer patients with pulmonary metastases in 56 cases, were randomly divided into observation group, (n=28) and control group (n=28), the control group were treated with stereotactic radiotherapy, the patients in the observation group were given on the basis of drug targeting cable Rafini treatment, clinical efficacy and safety comparison of two groups of patients. Results:The observation group the total efficiency was significantly higher than the control group (P<0.05), 1 years, 2 years survival rate was significantly higher than the control group (P<0.05), the median survival period was significantly longer than that of the control group (P<0.05); adverse reactions during the treatment of the two groups were specific difference in different degree, including fatigue, nausea, loss of appetite and bone marrow suppression; the incidence of adverse reactions was 78.57% (22/28), the control group adverse reaction rate was 85.71% (24/28) bone marrow suppression control group two groups of patients with adverse reaction incidence compared no significant difference, no statistical significance (=1.737, P>0.05). After treatment, the observation group of NK cells (71.43%) and IL-2 (78.57%) the total effective rate was significantly higher than that of the control group (39.29%, 46.43%), the difference was statistically significant (P < 0.05), showed that the patients in the observation group than the control group in improving immunity. Conclusion :The clinical efficacy of targeted drugs sorafenib combined with stereotactic radiotherapy for lung metastasis of liver cancer is good, can effectively prolong the median survival time, adverse reactions were mild, with the promotion of value.
【Key words】
Lung metastasis of liver cancer; Sola Fini; stereotactic radiotherapy